Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients

C. Fernández-Díaz¹, Rafael Melero ², Javier Loricera ³, Santos Castañeda ⁴, Francisco Ortiz-Sanjuán ⁵, I. Casafont-Solé ⁶, Carmen carrasco-Cubero ⁷, A. Juan-Mas ⁸, Raquel Almodovar-Gonzalez ⁹, S. Rodriguez-Garcia ¹⁰, R. Castellanos ¹¹, O. Maiz-Alonso ¹², C. Aguilera-Cros ¹³, I. Cabezas-rodriguéz ¹⁴, EC Cervantes ¹⁵, M. Moreno ¹⁶, L. Arboleya ¹⁷, C. Montagut ¹⁸, Patricia Carreira ¹⁹, C. Ojeda-Garcia ²⁰, Gema Bonilla ²¹, T. Perez-Sandoval ²², P. Vela ²³, JL Andreu ²⁴, Susana Romero-Yuste ²⁵, A. Urruticoechea-Arana ²⁶, E. Salgado-Pérez ²⁷, Cristina Hidalgo ²⁸, Javier Narváez ²⁹, E. Raya ³⁰, MJ. Moreno-Ramos ³¹, P. Morales-Garrido ³², L. Pérez-alba ³³, Carlos Fernández-López ³⁴, Ignacio Villa ³⁵, Noelia Álvarez-Rivas ³⁶, Juan María Blanco-Madrigal ³⁷, JR Jimenez-Aberasturi ³⁸, A. Perez-Linaza ³⁹, N. Del-val-del-amo ⁴⁰, Sabela Fernández ⁴¹, A. García-valle ⁴², C.A. Peralta-Ginés ⁴³, A. Garcia-Aparicio ⁴⁴, L. Exposito-pérez ⁴⁵, N. Mena-Vazquez ⁴⁶, R. López-Sánchez ⁴⁷, B. Garcia-magallon ⁴⁸, Miguel Angel González-Gay ⁴⁹ and Ricardo Blanco ⁵⁰, ¹HU Vinalopo, Madrid, Madrid, Spain, ²Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁶HU German Trias i pujol, BAacelona, ⁷CHU de Badajoz, Badajoz, Spain, ⁸H Son Llázer, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁰HU. Clinic, Barcelona, ¹¹Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ¹²HU Donostia, Donostia, Spain, ¹³hospital virgen del rocio, Sevilla, Spain, ¹⁴HU. Río Hortega, Valladolid, Spain, ¹⁵HU Santiago de compostela, Santiago, ¹⁶Parc Tauli Hospital Universitari, Sabadell, Spain, ¹⁷Hospital Central Asturias, OViedo, ¹⁸HCU Valladolid, Valladolid, Spain, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰HU Virgen de la Macarena, Sevilla, ²¹Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, ²²HU León, León, Spain, ²³Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, ²⁴HU Puerta del Hierro, Madrid, ²⁵Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ²⁶HU Can Misses, Ibiza, Spain, ²⁷C.H Ourense, Ourense, ²⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁹Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ³⁰Hospital San Cecilio, Granada, Andalucia, Spain, ³¹HU Arrixaca, Murcia, Spain, ³²Hospital San Cecilio, Granada, Spain, ³³HU San Cecilio, Granada, Spain, ³⁴Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ³⁵Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ³⁶Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, ³⁷Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, ³⁸HU Araba, Vitoria, Spain, ³⁹HU Puerta del Mar, Cadiz, ⁴⁰HU Navarra, Pamplona, Spain, ⁴¹Hospital Universitario San Agustín, Avilés, Asturias, Spain, ⁴²Rheumatology Department. Hospital Rio Carrión, Palencia, Spain, ⁴³HU Lozano Blesa, Zaragoza, ⁴⁴H Virgen de la salud, Toledo, Spain, ⁴⁵HU Canarias, Tenerife, Spain, ⁴⁶HU Malaga., Malaga, ⁴⁷Hospital Negrin, Tenerife, ⁴⁸H Huesca, HUesca, ⁴⁹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵⁰Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interstitial lung disease, rheumatoid arthritis (RA) and biologic drugs

Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial Lung Disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA).

Interstitial lung disease (ILD) associated with Rheumatoid Arthritis (RA) has a poor prognosis. Effectives treatments in RA such as anti-TNF have been implicated in the exacerbation of ILD.
Our objective was see the efficacy of Abatacept in ILD associated with RA.

Methods: Retrospective multicenter study of RA patients with ILD treated with ABA atleast for 3 doses. The ILD was diagnosed by HRCT. We have analyzed the following variables: a) 1-point change the Modified Medical Research Council (MMRC); b) FVC improvement or decline ≥10%; improvement or decrline ≥10% in DLCO c) radiological improvement in HRCT scan, d) changes in DAS28 score. e) prednisone dose. Values were compared with baseline.

Results: We studied 263 patients (150 women /113 men) with ILD associated to RA. The patients were smokers or exsmoker in a 53%. APCC was positive in 88.6%. The follow-up mean was 22.66±19.66 months. The mean age was 64.64 ± 10 years. The median to progression of ILD was 12 [3-41.25] months. The mean DLCO at onset was 65,68±18.33 and the FVC at onset was 85.88±21.77 111 patients were treated in monotherapy.
The most frequent pattern was UIP 41,6% 32,7% NSIP 24,7% “others” thats include mixed patterns BONO or BO.

The Figure1 expresses the evolution of the avalible data.
DAS28 also improved from 4.501±1.486 to 3.107±1.333 and we also appreciate a decrease in the dose of prednisone from the initial mean 7.5 [5-10] to the final mean 5mg [5-7.5]. The global mean of FVC at the end of follow up was 85.3±20.69 the global mean of DLCO at the end of follow up was 65.35±19.88 both similar to the onset mean.

Conclusion: Abatacept could be a relatively safe and effective treatment for patients with interstitial lung involvement associated with rheumatoid arthritis. However, should be verified in prospective and randomized studies.

Disclosure: C. Fernández-Díaz, Bristol Meyer, 8; R. Melero, None; J. Loricera, None; S. Castañeda, None; F. Ortiz-Sanjuán, None; I. Casafont-Solé, None; C. carrasco-Cubero, None; A. Juan-Mas, None; R. Almodovar-Gonzalez, None; S. Rodriguez-Garcia, None; R. Castellanos, None; O. Maiz-Alonso, None; C. Aguilera-Cros, None; I. Cabezas-rodriguéz, None; E. Cervantes, None; M. Moreno, None; L. Arboleya, None; C. Montagut, None; P. Carreira, None; C. Ojeda-Garcia, None; G. Bonilla, None; T. Perez-Sandoval, None; P. Vela, None; J. Andreu, None; S. Romero-Yuste, None; A. Urruticoechea-Arana, None; E. Salgado-Pérez, None; C. Hidalgo, None; J. Narváez, None; E. Raya, None; M. Moreno-Ramos, None; P. Morales-Garrido, None; L. Pérez-alba, None; C. Fernández-López, None; I. Villa, None; N. Álvarez-Rivas, None; J. Blanco-Madrigal, None; J. Jimenez-Aberasturi, None; A. Perez-Linaza, None; N. Del-val-del-amo, None; S. Fernández, None; A. García-valle, None; C. Peralta-Ginés, None; A. Garcia-Aparicio, None; L. Exposito-pérez, None; N. Mena-Vazquez, None; R. López-Sánchez, None; B. Garcia-magallon, None; M. González-Gay, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 2, 5, EliLilly, 2, 5, Jansen, 2, Janssen, 2, MSD, 2, 5, 8, Novartis, 2, 5, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, Sobi, 5, 8; R. Blanco, None.

To cite this abstract in AMA style:

Fernández-Díaz C, Melero R, Loricera J, Castañeda S, Ortiz-Sanjuán F, Casafont-Solé I, carrasco-Cubero C, Juan-Mas A, Almodovar-Gonzalez R, Rodriguez-Garcia S, Castellanos R, Maiz-Alonso O, Aguilera-Cros C, Cabezas-rodriguéz I, Cervantes E, Moreno M, Arboleya L, Montagut C, Carreira P, Ojeda-Garcia C, Bonilla G, Perez-Sandoval T, Vela P, Andreu J, Romero-Yuste S, Urruticoechea-Arana A, Salgado-Pérez E, Hidalgo C, Narváez J, Raya E, Moreno-Ramos M, Morales-Garrido P, Pérez-alba L, Fernández-López C, Villa I, Álvarez-Rivas N, Blanco-Madrigal J, Jimenez-Aberasturi J, Perez-Linaza A, Del-val-del-amo N, Fernández S, García-valle A, Peralta-Ginés C, Garcia-Aparicio A, Exposito-pérez L, Mena-Vazquez N, López-Sánchez R, Garcia-magallon B, González-Gay M, Blanco R. Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/abatacept-in-rheumatoid-arthritis-with-interstitial-lung-disease-a-retrospective-multicenter-study-of-263-patients/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abatacept-in-rheumatoid-arthritis-with-interstitial-lung-disease-a-retrospective-multicenter-study-of-263-patients/